Table A14.3NMA results for All-cause Mortality

Standard
Adjusted-Dose
Warfarin
Apixaban 5
mg b.i.d.
Dabigatran
110 mg b.i.d.
Dabigatran
150 mg b.i.d.
Rivaroxaban
20 mg OD
No
treatment/Placebo
LDASAMDASA
Apixaban 5 mg b.i.d.0.89(0.794,0.997)
Dabigatran 110 mg b.i.d.0.91(0.8,1.04)1.02(0.86,1.22)
Dabigatran 150 mg b.i.d.0.88(0.77,1.01)0.99(0.83,1.18)0.97(0.85,1.11)
Rivaroxaban 20 mg OD0.92(0.82,1.03)1.03(0.88,1.22)1.01(0.85,1.21)1.04(0.87,1.24)
No treatment/Placebo0.93(0.54,1.59)1.05(0.6,1.81)1.02(0.59,1.78)1.05(0.61,1.83)1.01(0.58,1.75)
LDASA0.99(0.74,1.32)1.11(0.81,1.52)1.08(0.79,1.5)1.12(0.81,1.54)1.07(0.78,1.47)1.06(0.62,1.82)
MDASA0.95(0.52,1.72)1.07(0.58,1.96)1.04(0.56,1.91)1.07(0.58,1.97)1.03(0.56,1.88)1.02(0.53,1.96)0.96(0.51,1.82)
Clopidogrel 75 mg OD & LDASA1.02(0.81,1.28)1.14(0.89,1.47)1.12(0.86,1.45)1.15(0.89,1.5)1.11(0.86,1.42)1.09(0.61,1.96)1.03(0.71,1.49)1.08(0.57,2.04)

From: APPENDIX 14, PAIRWISE COMPARISONS FROM NETWORK META-ANALYSIS

Cover of Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation
Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation [Internet].
Copyright © CADTH February 2013.

You are permitted to make copies of this document for Non-commercial purposes provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish or redistribute any material from the website in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.